202 related articles for article (PubMed ID: 22996758)
21. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation.
Gacci M; Vignozzi L; Sebastianelli A; Salvi M; Giannessi C; De Nunzio C; Tubaro A; Corona G; Rastrelli G; Santi R; Nesi G; Serni S; Carini M; Maggi M
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):101-6. PubMed ID: 23165431
[TBL] [Abstract][Full Text] [Related]
22. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue.
Uckert S; Sormes M; Kedia G; Scheller F; Knapp WH; Jonas U; Stief CG
Urology; 2008 Mar; 71(3):526-30. PubMed ID: 18342202
[TBL] [Abstract][Full Text] [Related]
23. Phosphodiesterase type 5 inhibitor attenuates chronic ischemia-induced prostatic hyperplasia in a rat model.
Fujii S; Yamashita S; Hayashi N; Goto T; Koyama J; Sato T; Shimada S; Kawasaki Y; Izumi H; Kawamorita N; Mitsuzuka K; Ito A; Arai Y
Prostate; 2019 Apr; 79(5):536-543. PubMed ID: 30593704
[TBL] [Abstract][Full Text] [Related]
24. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
Tinel H; Stelte-Ludwig B; Hütter J; Sandner P
BJU Int; 2006 Dec; 98(6):1259-63. PubMed ID: 16956354
[TBL] [Abstract][Full Text] [Related]
25. PDE5 inhibitors for LUTS.
Mouli S; McVary KT
Prostate Cancer Prostatic Dis; 2009; 12(4):316-24. PubMed ID: 19687801
[TBL] [Abstract][Full Text] [Related]
26. Tadalafil reduces visceral adipose tissue accumulation by promoting preadipocytes differentiation towards a metabolically healthy phenotype: Studies in rabbits.
Maneschi E; Cellai I; Aversa A; Mello T; Filippi S; Comeglio P; Bani D; Guasti D; Sarchielli E; Salvatore G; Morelli A; Mazzanti B; Corcetto F; Corno C; Francomano D; Galli A; Vannelli GB; Lenzi A; Mannucci E; Maggi M; Vignozzi L
Mol Cell Endocrinol; 2016 Mar; 424():50-70. PubMed ID: 26805634
[TBL] [Abstract][Full Text] [Related]
27. Activation of cGMP/PKG/p65 signaling associated with PDE5-Is downregulates CCL5 secretion by CD8
Jin S; Xiang P; Liu J; Yang Y; Hu S; Sheng J; He Q; Yu W; Han W; Jin J; Peng J
Prostate; 2019 Jun; 79(8):909-919. PubMed ID: 30958912
[TBL] [Abstract][Full Text] [Related]
28. Metabolic syndrome-associated sperm alterations in an experimental rabbit model: relation with metabolic profile, testis and epididymis gene expression and effect of tamoxifen treatment.
Marchiani S; Vignozzi L; Filippi S; Gurrieri B; Comeglio P; Morelli A; Danza G; Bartolucci G; Maggi M; Baldi E
Mol Cell Endocrinol; 2015 Feb; 401():12-24. PubMed ID: 25451982
[TBL] [Abstract][Full Text] [Related]
29. Regulation of PDE5 expression in normal prostate, benign prostatic hyperplasia, and adenocarcinoma.
Bisegna C; Gravina GL; Pierconti F; Martini M; Larocca L; Rossi P; Grimaldi P; Dolci S; Di Stasi S; Jannini EA
Andrology; 2020 Mar; 8(2):427-433. PubMed ID: 31433119
[TBL] [Abstract][Full Text] [Related]
30. Increased phosphodiesterase type 5 levels in a mouse model of type 2 diabetes mellitus.
Ellati RT; Dokun AO; Kavoussi PK; Steers WD; Annex BH; Lysiak JJ
J Sex Med; 2013 Feb; 10(2):362-9. PubMed ID: 22812665
[TBL] [Abstract][Full Text] [Related]
31. Phosphodiesterase type 5 inhibition reverts prostate fibroblast-to-myofibroblast trans-differentiation.
Zenzmaier C; Kern J; Sampson N; Heitz M; Plas E; Untergasser G; Berger P
Endocrinology; 2012 Nov; 153(11):5546-55. PubMed ID: 22948216
[TBL] [Abstract][Full Text] [Related]
32. Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence.
Martínez-Salamanca JI; Carballido J; Eardley I; Giuliano F; Gratzke C; Rosen R; Salonia A; Stief C
Eur Urol; 2011 Sep; 60(3):527-35. PubMed ID: 21684677
[TBL] [Abstract][Full Text] [Related]
33. Novel imaging of the prostate reveals spontaneous gland contraction and excretory duct quiescence together with different drug effects.
Kügler R; Mietens A; Seidensticker M; Tasch S; Wagenlehner FM; Kaschtanow A; Tjahjono Y; Tomczyk CU; Beyer D; Risbridger GP; Exintaris B; Ellem SJ; Middendorff R
FASEB J; 2018 Mar; 32(3):1130-1138. PubMed ID: 29089445
[TBL] [Abstract][Full Text] [Related]
34. Phosphodiesterase type 5 (PDE5) is co-localized with key proteins of the nitric oxide/cyclic GMP signaling in the human prostate.
Ückert S; Waldkirch ES; Merseburger AS; Kuczyk MA; Oelke M; Hedlund P
World J Urol; 2013 Jun; 31(3):609-14. PubMed ID: 23475211
[TBL] [Abstract][Full Text] [Related]
35. Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Zhao C; Kim SH; Lee SW; Jeon JH; Kang KK; Choi SB; Park JK
BJU Int; 2011 Jun; 107(12):1943-7. PubMed ID: 21054754
[TBL] [Abstract][Full Text] [Related]
36. Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia.
Vikram A; Jena GB; Ramarao P
Prostate; 2010 Jan; 70(1):79-89. PubMed ID: 19790233
[TBL] [Abstract][Full Text] [Related]
37. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum.
Zhang XH; Morelli A; Luconi M; Vignozzi L; Filippi S; Marini M; Vannelli GB; Mancina R; Forti G; Maggi M
Eur Urol; 2005 Mar; 47(3):409-16; discussion 416. PubMed ID: 15716209
[TBL] [Abstract][Full Text] [Related]
38. FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS.
Maneschi E; Vignozzi L; Morelli A; Mello T; Filippi S; Cellai I; Comeglio P; Sarchielli E; Calcagno A; Mazzanti B; Vettor R; Vannelli GB; Adorini L; Maggi M
J Endocrinol; 2013; 218(2):215-31. PubMed ID: 23750014
[TBL] [Abstract][Full Text] [Related]
39. Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
Roumeguère T; Zouaoui Boudjeltia K; Hauzeur C; Schulman C; Vanhaeverbeek M; Wespes E
BJU Int; 2009 Aug; 104(4):511-7. PubMed ID: 19239452
[TBL] [Abstract][Full Text] [Related]
40. Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation.
Vignozzi L; Gacci M; Cellai I; Santi R; Corona G; Morelli A; Rastrelli G; Comeglio P; Sebastanelli A; Maneschi E; Nesi G; De Nunzio C; Tubaro A; Mannucci E; Carini M; Maggi M
Prostate; 2013 Jun; 73(8):789-800. PubMed ID: 23620238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
